Table 1.
Total (n = 39) | |
---|---|
Age years (mean ± SD) | 62.3 ± 13.2 |
Male, n (%) | 21 (54) |
Race, n (%) | |
Asian | 4 (10) |
Black | 3 (8) |
White | 26 (67) |
Other/unknown | 6 (15) |
Comorbidities, n (%) | |
Obesity (BMI > 30 kg/m2) | 8 (21) |
Hypertension | 17 (44) |
Diabetes | 5 (13) |
Any comorbidity | 21 (54) |
Time from diagnosis to treatment, days, mean (SD) | 7.4 ± 3.8 |
Total remdesivir doses, median (IQR) | 5 (2-5) |
Other therapies, n (%) | |
Oxygen | 29 (74) |
Glucocorticoids* | 33 (85) |
Monoclonal antibody | 10 (26) |
Prophylactic anticoagulation† | 14 (36) |
Glucocorticoids include both dexamethasone and prednisone.
Prophylactic anticoagulation includes both rivaroxaban and apixaban.